PE20050249A1 - Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos - Google Patents

Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos

Info

Publication number
PE20050249A1
PE20050249A1 PE2004000665A PE2004000665A PE20050249A1 PE 20050249 A1 PE20050249 A1 PE 20050249A1 PE 2004000665 A PE2004000665 A PE 2004000665A PE 2004000665 A PE2004000665 A PE 2004000665A PE 20050249 A1 PE20050249 A1 PE 20050249A1
Authority
PE
Peru
Prior art keywords
alkyl
cyanopyrrolides
medicines
procedure
preparation
Prior art date
Application number
PE2004000665A
Other languages
English (en)
Inventor
Karl Schoenafinger
Holger Wagner
Gerhard Jaehne
Holger Gaul
Christian Buning
Georg Tschank
Ulrich Werner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10333935A external-priority patent/DE10333935A1/de
Priority claimed from DE102004019276A external-priority patent/DE102004019276A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20050249A1 publication Critical patent/PE20050249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A CIANO PIRROLIDIDAS SUSTITUIDAS DE FORMULA I Y A SUS SALES, DONDE R1 ES H, ALQUILO C1-C10, CICLOALQUILO C3-C10, ENTRE OTROS; R2 ES H, ALQUILO C1-C10, ALQUENILO C2-C6, ENTRE OTROS. EL MEDICAMENTO RESULTANTE TAMBIEN COMPRENDE OTROS COMPONENTES COMO UNO O MAS ANTIDIABETICOS, INDUCTORES DE RECEPTORES DE LDL, AGONISTAS DE PPAR GAMMA, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL METABOLISMO COMO DIABETES TIPO 2, EN MANIFESTACIONES ARTERIOESCLEROTICAS, EN RESISTENCIA A INSULINA, ENTRE OTROS
PE2004000665A 2003-07-25 2004-07-13 Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos PE20050249A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10333935A DE10333935A1 (de) 2003-07-25 2003-07-25 Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004019276A DE102004019276A1 (de) 2004-04-21 2004-04-21 Neue Cyanopyrrolidide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20050249A1 true PE20050249A1 (es) 2005-06-01

Family

ID=34117368

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000665A PE20050249A1 (es) 2003-07-25 2004-07-13 Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos

Country Status (13)

Country Link
EP (1) EP1651649B1 (es)
JP (1) JP2006528601A (es)
AR (1) AR045080A1 (es)
AT (1) ATE490256T1 (es)
AU (1) AU2004261364A1 (es)
BR (1) BRPI0412900A (es)
CA (1) CA2534267A1 (es)
DE (1) DE502004011957D1 (es)
IL (1) IL173204A0 (es)
MX (1) MXPA06000634A (es)
PE (1) PE20050249A1 (es)
TW (1) TW200524936A (es)
WO (1) WO2005012308A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
CN109867679B (zh) * 2019-04-11 2021-11-30 杭州瀚康生物医药科技有限公司 盐酸吡西卡尼中间体的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2997894B2 (ja) * 1990-11-07 2000-01-11 株式会社三和化学研究所 循環器系疾患の予防及び治療剤
WO1999031507A1 (en) * 1997-12-18 1999-06-24 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries

Also Published As

Publication number Publication date
TW200524936A (en) 2005-08-01
IL173204A0 (en) 2006-06-11
AR045080A1 (es) 2005-10-12
MXPA06000634A (es) 2006-08-23
ATE490256T1 (de) 2010-12-15
CA2534267A1 (en) 2005-02-10
JP2006528601A (ja) 2006-12-21
EP1651649B1 (de) 2010-12-01
DE502004011957D1 (de) 2011-01-13
AU2004261364A1 (en) 2005-02-10
WO2005012308A1 (de) 2005-02-10
BRPI0412900A (pt) 2006-10-31
EP1651649A1 (de) 2006-05-03

Similar Documents

Publication Publication Date Title
PE20050249A1 (es) Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
ZA202205346B (en) Glp-1 receptor agonist and use thereof
CO6160319A2 (es) Moduladores del metabolismo y tratamiento de los trastornos metabolicos
PE20071320A1 (es) Moduladores de receptores cannabinoides
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
CO6160320A2 (es) Moduladores del metabolismo y tratamiento de los trastornos metabolicos
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
CL2008002227A1 (es) Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad.
CL2008002052A1 (es) Compuestos derivados de pirazol, inhibidores de la 11 beta-hidroxi-esteroide-deshidrogenasa; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y uso para la preparacion de medicamentos para el tratamiento de diabetes, obesidad, trastornos de ingestion de comida o dislipidemia
PE20040599A1 (es) Amidas sustituidas como moduladores del receptor cannabinoide-1 (cb1)
CO6650337A2 (es) Derivados de 3- hidroxi-5 -arilisotiazol novedoso
CR11849A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
UY27518A1 (es) Nuevos derivados de pirrolidina
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
CL2007003261A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, tales como esquizofrenia,
UY27666A1 (es) Nuevos derivados de piridina y quinolina
ES2687651T3 (es) Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
GT200600429A (es) Compuestos organicos
PE20081878A1 (es) Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
MA27707A1 (fr) Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
UY27069A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona

Legal Events

Date Code Title Description
FC Refusal